151 results on '"Grünhagen, D J"'
Search Results
2. Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases
- Author
-
Meyer, Y. M., Wilting, S. M., Kraan, J., Olthof, P., Vermeulen, P., Martens, J., Grünhagen, D. J., Sleijfer, S., and Verhoef, C.
- Published
- 2023
- Full Text
- View/download PDF
3. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
- Author
-
Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P. H., Rinkes, I. H. M. Borel, Breitenstein, S., Bruijnen, R. C. G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K. Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Å., Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K. G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L. J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A. J., Binkert, C. A., Bemelmans, M. H. A., van der Leij, C., Schadde, E., and van Dam, R. M.
- Published
- 2022
- Full Text
- View/download PDF
4. Maligne tumoren van de weke delen
- Author
-
van der Graaf, W. T. A., primary, Bovée, J. V. M. G., additional, Haas, R. L. M., additional, and Grünhagen, D. J., additional
- Published
- 2020
- Full Text
- View/download PDF
5. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy
- Author
-
Höppener, D. J., Nierop, P. M. H., Herpel, E., Rahbari, N. N., Doukas, M., Vermeulen, P. B., Grünhagen, D. J., and Verhoef, C.
- Published
- 2019
- Full Text
- View/download PDF
6. Evaluating task-specific augmentations in self-supervised pre-training for 3D medical image analysis
- Author
-
Colliot, Olivier, Mitra, Jhimli, Claessens, C. H. B., Hamm, J. J. M., Viviers, C. G. A., Nederend, J., Grünhagen, D. J., Tanis, P. J., de With, P. H. N., and van der Sommen, F.
- Published
- 2024
- Full Text
- View/download PDF
7. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases – the multicenter randomized controlled PUMP trial
- Author
-
Buisman, F. E., Homs, M. Y. V., Grünhagen, D. J., Filipe, W. F., Bennink, R. J., Besselink, M. G. H., Borel Rinkes, I. H. M., Bruijnen, R. C. G., Cercek, A., D’Angelica, M. I., van Delden, O. M., Donswijk, M. L., van Doorn, L., Doornebosch, P. G., Emmering, J., Erdmann, J. I., IJzerman, N. S., Grootscholten, C., Hagendoorn, J., Kemeny, N. E., Kingham, T. P., Klompenhouwer, E. G., Kok, N. F. M., Koolen, S., Kuhlmann, K. F. D., Kuiper, M. C., Lam, M. G. E., Mathijssen, R. H. J., Moelker, A., Oomen-de Hoop, E., Punt, C. J. A., te Riele, W. W., Roodhart, J. M. L., Swijnenburg, R. J., Prevoo, W., Tanis, P. J., Vermaas, M., Versleijen, M. W. J., Veuger, F. P., Weterman, M. J., Verhoef, C., and Groot Koerkamp, B.
- Published
- 2019
- Full Text
- View/download PDF
8. Circulating tumour cells are associated with histopathological growth patterns of colorectal cancer liver metastases
- Author
-
Meyer, Y. M., primary, Wilting, S. M., additional, Kraan, J., additional, Olthof, P., additional, Vermeulen, P., additional, Martens, J., additional, Grünhagen, D. J., additional, Sleijfer, S., additional, and Verhoef, C., additional
- Published
- 2022
- Full Text
- View/download PDF
9. Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin
- Author
-
Verver, D., Madu, M. F., Oude Ophuis, C. M. C., Faut, M., de Wilt, J. H. W., Bonenkamp, J. J., Grünhagen, D. J., van Akkooi, A. C. J., Verhoef, C., and van Leeuwen, B. L.
- Published
- 2018
- Full Text
- View/download PDF
10. Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases: Can the Extent of Surgery be Safely Minimized?: A Retrospective, Multicenter Cohort Study
- Author
-
Oude Ophuis, C. M. C., van Akkooi, A. C. J., Hoekstra, H. J., Bonenkamp, J. J., van Wissen, J., Niebling, M. G., de Wilt, J. H. W., van der Hiel, B., van de Wiel, B., Koljenović, S., Grünhagen, D. J., and Verhoef, C.
- Published
- 2015
- Full Text
- View/download PDF
11. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy.
- Author
-
UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, UCL - SSS/IREC/IMAG - Pôle d'imagerie médicale, UCL - SSS/IREC/GAEN - Pôle d'Hépato-gastro-entérologie, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service de chirurgie, UCL - (MGD) Service de radiologie - résonance magnétique, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Claude, Bertrand, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, Jean-François, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, Alexandra, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M
- Abstract
The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Not applicable. DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).
- Published
- 2022
12. Dragon 1 Protocol Manuscript:Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
- Author
-
Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., van Dam, R. M., Korenblik, R., Olij, B., Aldrighetti, L. A., Hilal, M. Abu, Ahle, M., Arslan, B., van Baardewijk, L. J., Baclija, I., Bent, C., Bertrand, C. L., Björnsson, B., de Boer, M. T., de Boer, S. W., Bokkers, R. P.H., Rinkes, I. H.M.Borel, Breitenstein, S., Bruijnen, R. C.G., Bruners, P., Büchler, M. W., Camacho, J. C., Cappelli, A., Carling, U., Chan, B. K.Y., Chang, D. H., choi, J., Font, J. Codina, Crawford, M., Croagh, D., Cugat, E., Davis, R., De Boo, D. W., De Cobelli, F., De Wispelaere, J. F., van Delden, O. M., Delle, M., Detry, O., Díaz-Nieto, R., Dili, A., Erdmann, J. I., Fisher, O., Fondevila, C., Fretland, Borobia, F. Garcia, Gelabert, A., Gérard, L., Giuliante, F., Gobardhan, P. D., Gómez, F., Grünberger, T., Grünhagen, D. J., Guitart, J., Hagendoorn, J., Heil, J., Heise, D., Herrero, E., Hess, G. F., Hoffmann, M. H., Iezzi, R., Imani, F., Nguyen, J., Jovine, E., Kalff, J. C., Kazemier, G., Kingham, T. P., Kleeff, J., Kollmar, O., Leclercq, W. K.G., Ben, S. Lopez, Lucidi, V., MacDonald, A., Madoff, D. C., Manekeller, S., Martel, G., Mehrabi, A., Mehrzad, H., Meijerink, M. R., Menon, K., Metrakos, P., Meyer, C., Moelker, A., Modi, S., Montanari, N., Navines, J., Neumann, U. P., Peddu, P., Primrose, J. N., Qu, X., Raptis, D., Ratti, F., Ridouani, F., Rogan, C., Ronellenfitsch, U., Ryan, S., Sallemi, C., Moragues, J. Sampere, Sandström, P., Sarriá, L., Schnitzbauer, A., Serenari, M., Serrablo, A., Smits, M. L.J., Sparrelid, E., Spüntrup, E., Stavrou, G. A., Sutcliffe, R. P., Tancredi, I., Tasse, J. C., Udupa, V., Valenti, D., Fundora, Y., Vogl, T. J., Wang, X., White, S. A., Wohlgemuth, W. A., Yu, D., Zijlstra, I. A.J., Binkert, C. A., Bemelmans, M. H.A., van der Leij, C., Schadde, E., and van Dam, R. M.
- Abstract
Study Purpose: The DRAGON 1 trial aims to assess training, implementation, safety and feasibility of combined portal- and hepatic-vein embolization (PVE/HVE) to accelerate future liver remnant (FLR) hypertrophy in patients with borderline resectable colorectal cancer liver metastases. Methods: The DRAGON 1 trial is a worldwide multicenter prospective single arm trial. The primary endpoint is a composite of the safety of PVE/HVE, 90-day mortality, and one year accrual monitoring of each participating center. Secondary endpoints include: feasibility of resection, the used PVE and HVE techniques, FLR-hypertrophy, liver function (subset of centers), overall survival, and disease-free survival. All complications after the PVE/HVE procedure are documented. Liver volumes will be measured at week 1 and if applicable at week 3 and 6 after PVE/HVE and follow-up visits will be held at 1, 3, 6, and 12 months after the resection. Results: Not applicable. Conclusion: DRAGON 1 is a prospective trial to assess the safety and feasibility of PVE/HVE. Participating study centers will be trained, and procedures standardized using Work Instructions (WI) to prepare for the DRAGON 2 randomized controlled trial. Outcomes should reveal the accrual potential of centers, safety profile of combined PVE/HVE and the effect of FLR-hypertrophy induction by PVE/HVE in patients with CRLM and a small FLR. Trial Registration: Clinicaltrials.gov: NCT04272931 (February 17, 2020). Toestingonline.nl: NL71535.068.19 (September 20, 2019).
- Published
- 2022
13. Propensity score matching demonstrates similar results for radiofrequency ablation compared to surgical resection in colorectal liver metastases
- Author
-
van de Geest, T W, van Amerongen, M J, Nierop, P M H, Höppener, D J, Grünhagen, D J, Moelker, A, Fütterer, J J, Verhoef, C, de Wilt, J H W, van de Geest, T W, van Amerongen, M J, Nierop, P M H, Höppener, D J, Grünhagen, D J, Moelker, A, Fütterer, J J, Verhoef, C, and de Wilt, J H W
- Abstract
PURPOSE: Minimally invasive ablative treatments, such as radiofrequency ablation (RFA), are increasingly used in the curative treatment of patients with colorectal liver metastases (CRLM). Selection bias plays an important role in the evaluation of early and late results between RFA and surgery. The purpose of this study was to evaluate recurrences and oncological survival following these two treatment modalities using single pair propensity score matching.METHODS: Between 2000 and 2018, patients curatively treated for CRLM were included in a multicentre database. Patients were excluded when receiving two-staged treatment, synchronous treatment with primary tumor or combination of modalities. Propensity score matching was used to minimize influence of known covariates, i.e., age, ASA, FONG CRS, location and T-stage of the primary tumor.RESULTS: Before matching, the RFA group contained 39 patients and the surgery group 982 patients, after matching both groups contained 36 patients. After matching, mean age was 69 years (53-86) for RFA and 68 (50-86) for surgery, with a mean tumor size of respectively 2.5 cm (0.8-6.5) and 3.4 cm (1-7.5). Both groups showed similar complication rate according to Clavien-Dindo (17vs.33%; p = 0.18), recurrence rate (58vs.64%; p = 0.09) without significant differences in 5-year DFS and OS (RFA compared to surgery respectively 25vs.37%; p = 0.09 and 42vs.53%; p = 0.09).CONCLUSION: After propensity score matching, RFA showed lower complications and similar oncological survival compared to surgical resection. In patients who are suboptimal candidates for surgery, RFA seems to be a good and safe alternative.
- Published
- 2022
14. The meaning of screening:detection of brain metastasis in the adjuvant setting for stage III melanoma
- Author
-
Derks, S. H.A.E., de Joode, K., Mulder, E. E.A.P., Ho, L. S., Joosse, A., de Jonge, M. J.A., Verhoef, C., Grünhagen, D. J., Smits, M., van den Bent, M. J., van der Veldt, A. A.M., Derks, S. H.A.E., de Joode, K., Mulder, E. E.A.P., Ho, L. S., Joosse, A., de Jonge, M. J.A., Verhoef, C., Grünhagen, D. J., Smits, M., van den Bent, M. J., and van der Veldt, A. A.M.
- Abstract
BACKGROUND: The incidence of melanoma is increasing and 37% of patients with metastatic melanoma eventually have brain metastasis (BM). Currently, there is no consensus on screening for BM in patients with resected stage III melanoma. However, given the high incidence of BM, routine screening magnetic resonance imaging (MRI) of the brain is considered in patients with completely resected stage III melanoma before the start of adjuvant treatment. The aim of this study was to assess the yield of screening for BM in these patients.MATERIALS AND METHODS: A single-center cohort study was carried out in the Erasmus MC, Rotterdam, The Netherlands, a large tertiary referral center for patients with melanoma. Eligible patients with complete resection of stage III melanoma and a screening MRI of the brain, made within 12 weeks after resection and before adjuvant treatment (programmed cell death protein 1 inhibitors, dabrafenib-trametinib), available between 1 August 2018 and 1 January 2021, were included.RESULTS: A total of 202 patients were included. Eighteen (8.9%) of 202 patients had extracranial metastasis at screening. Two (1.1%) of the remaining 184 patients had BM at screening, resulting in a switch from adjuvant treatment to ipilimumab-nivolumab. At a median follow-up of 21.2 months, BM was detected in another 4 (2.4%) of 166 patients who started with adjuvant treatment.CONCLUSIONS: The yield of screening MRI of the brain is low after complete resection of stage III melanoma, before the start of adjuvant treatment. Therefore, routine screening MRI is not recommended in this setting.
- Published
- 2022
15. Treatment of metachronous colorectal cancer metastases in the Netherlands:A population-based study
- Author
-
Meyer, Y, Olthof, P B, Grünhagen, D J, de Hingh, I, de Wilt, J H W, Verhoef, C, Elferink, M A G, Meyer, Y, Olthof, P B, Grünhagen, D J, de Hingh, I, de Wilt, J H W, Verhoef, C, and Elferink, M A G
- Abstract
Background: This study aimed to describe the treatment of metachronous colorectal cancer metastases in a recent population-based cohort. Method: Patients with stage I-III colorectal cancer (CRC), diagnosed between January 1st and June 30th , 2015 who were surgically treated with curative intent were selected from the Netherlands Cancer Registry. Follow-up was at least 3 years after diagnosis of the primary tumour. Treatment of metachronous metastases was categorized into local treatment, systemic treatment, and best supportive care. Overall survival was estimated using Kaplan-Meier method. Results: Out of 5412 patients, 782 (14%) developed metachronous metastases, of whom 393 (50%) underwent local treatment (LT) with or without systemic therapy, 30% of patients underwent only systemic therapy (ST) and 19% only best supportive care (BSC). The most common metastatic site was the liver (51%) followed by lungs (33%) and peritoneum (22%). LT rates were 69%, 66%, and 44% for liver-only, lung-only and, peritoneal-only metastases respectively. Patients receiving LT and ST were significantly younger than patients receiving LT alone, while patients receiving BSC were significantly older than the other groups (p < 0.001). Patients with liver-only or lung-only metastases had a 3-year OS of 50.2% (43.3–56.7 95% CI) and 61.5% (50.7–70.6 95% CI) respectively. Patients with peritoneal-only disease had a lower 3-year OS, 18.1% (10.1–28.0 95% CI). Conclusion: Patients with metastases confined to the liver and lung have the highest rates of local treatment for metachronous metastatic colorectal cancer. The number of patients who underwent local treatment is higher than reported in previous Dutch and international studies.
- Published
- 2022
16. Sex differences in patients with gastrointestinal stromal tumours:do they exist and does it affect survival?
- Author
-
IJzerman, N S, van Werkhoven, E, Mohammadi, M, Hollander, D den, Bleckman, R F, Reyners, A K L, Desar, I M E, Gelderblom, H, Grünhagen, D J, Mathijssen, R H J, Steeghs, N, van der Graaf, W T A, IJzerman, N S, van Werkhoven, E, Mohammadi, M, Hollander, D den, Bleckman, R F, Reyners, A K L, Desar, I M E, Gelderblom, H, Grünhagen, D J, Mathijssen, R H J, Steeghs, N, and van der Graaf, W T A
- Abstract
BACKGROUND: Sex differences in cancer have gained attention in recent years. The role of sex as a prognostic factor in gastrointestinal stromal tumours (GIST) has not been well established. The aim of this research was to elucidate potential sex differences in GIST patients and the influence of sex on disease-specific survival (DSS).METHODS: A review of the literature was carried out to obtain an overview of all literature with sex as a covariate on GIST survival analyses. Furthermore, in the Dutch GIST Registry, GIST characteristics between males and females were compared and the influence of sex on DSS was analysed.RESULTS: A total of 118 articles from the review of the literature met our selection criteria; 58% of the articles found no sex difference in survival and 42% did find a sex difference. All differences favoured female patients, although there was substantial overlap of individual patients in the various reported groups. The Dutch GIST Registry cohort consisted of 1425 patients (46% female). Compared with female patients, male patients had larger tumours (mean 9.0 cm versus 7.9 cm) and higher mitotic rates (34.4% versus 28.0% >5 mitoses/5 mm2). GIST in males was more often metastasized at diagnosis (21.3% versus 13.7%) and incurable (38.5% versus 31.0%). Male patients less often received surgery of the primary tumour (71.7% versus 78.9%), but did experience more tumour ruptures (18.2% versus 13.3%). Male patients had a worse DSS than females. This was not statistically significant when corrected for differences in GIST characteristics.CONCLUSIONS: In case of sex differences in GIST in the literature, male patients have a worse outcome. In our Dutch GIST cohort a similar finding was made, but sex was shown not to be an independent factor. Male patients more often had aggressive GISTs, with larger tumours, higher mitotic rates, more tumour ruptures, and metastases, which could explain the sex differences in DSS.
- Published
- 2022
17. Dragon 1 Protocol Manuscript: Training, Accreditation, Implementation and Safety Evaluation of Portal and Hepatic Vein Embolization (PVE/HVE) to Accelerate Future Liver Remnant (FLR) Hypertrophy
- Author
-
Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, van Dam, R M, Zorgeenheid Orthopaedie Medisch, MS Radiologie, MS CGO, Regenerative Medicine and Stem Cells, Cancer, Other research (not in main researchprogram), Experimentele Afdeling Longziekten, Korenblik, R, Olij, B, Aldrighetti, L A, Hilal, M Abu, Ahle, M, Arslan, B, van Baardewijk, L J, Baclija, I, Bent, C, Bertrand, C L, Björnsson, B, de Boer, M T, de Boer, S W, Bokkers, R P H, Rinkes, I H M Borel, Breitenstein, S, Bruijnen, R C G, Bruners, P, Büchler, M W, Camacho, J C, Cappelli, A, Carling, U, Chan, B K Y, Chang, D H, Choi, J, Font, J Codina, Crawford, M, Croagh, D, Cugat, E, Davis, R, De Boo, D W, De Cobelli, F, De Wispelaere, J F, van Delden, O M, Delle, M, Detry, O, Díaz-Nieto, R, Dili, A, Erdmann, J I, Fisher, O, Fondevila, C, Fretland, Å, Borobia, F Garcia, Gelabert, A, Gérard, L, Giuliante, F, Gobardhan, P D, Gómez, F, Grünberger, T, Grünhagen, D J, Guitart, J, Hagendoorn, J, Heil, J, Heise, D, Herrero, E, Hess, G F, Hoffmann, M H, Iezzi, R, Imani, F, Nguyen, J, Jovine, E, Kalff, J C, Kazemier, G, Kingham, T P, Kleeff, J, Kollmar, O, Leclercq, W K G, Ben, S Lopez, Lucidi, V, MacDonald, A, Madoff, D C, Manekeller, S, Martel, G, Mehrabi, A, Mehrzad, H, Meijerink, M R, Menon, K, Metrakos, P, Meyer, C, Moelker, A, Modi, S, Montanari, N, Navines, J, Neumann, U P, Peddu, P, Primrose, J N, Qu, X, Raptis, D, Ratti, F, Ridouani, F, Rogan, C, Ronellenfitsch, U, Ryan, S, Sallemi, C, Moragues, J Sampere, Sandström, P, Sarriá, L, Schnitzbauer, A, Serenari, M, Serrablo, A, Smits, M L J, Sparrelid, E, Spüntrup, E, Stavrou, G A, Sutcliffe, R P, Tancredi, I, Tasse, J C, Udupa, V, Valenti, D, Fundora, Y, Vogl, T J, Wang, X, White, S A, Wohlgemuth, W A, Yu, D, Zijlstra, I A J, Binkert, C A, Bemelmans, M H A, van der Leij, C, Schadde, E, and van Dam, R M
- Published
- 2022
18. Meta-analysis of the influence of surgical margin and adjuvant radiotherapy on local recurrence after resection of sporadic desmoid-type fibromatosis
- Author
-
Janssen, M. L., van Broekhoven, D. L. M., Cates, J. M. M., Bramer, W. M., Nuyttens, J. J., Gronchi, A., Salas, S., Bonvalot, S., Grünhagen, D. J., and Verhoef, C.
- Published
- 2017
- Full Text
- View/download PDF
19. Propensity score matching demonstrates similar results for radiofrequency ablation compared to surgical resection in colorectal liver metastases
- Author
-
van de Geest, T. W., van Amerongen, M. J., Nierop, P. M. H., Höppener, D. J., Grünhagen, D. J., Moelker, A., Fütterer, J. J., Verhoef, C., de Wilt, J. H. W., Surgery, and Radiology & Nuclear Medicine
- Subjects
Radiofrequency Ablation ,Liver Neoplasms ,General Medicine ,Survival Rate ,Tumours of the digestive tract Radboud Institute for Health Sciences [Radboudumc 14] ,Treatment Outcome ,Oncology ,Urological cancers Radboud Institute for Health Sciences [Radboudumc 15] ,Catheter Ablation ,Hepatectomy ,Humans ,Surgery ,Neoplasm Recurrence, Local ,Colorectal Neoplasms ,Propensity Score ,Aged ,Retrospective Studies - Abstract
Contains fulltext : 251553.pdf (Publisher’s version ) (Open Access) PURPOSE: Minimally invasive ablative treatments, such as radiofrequency ablation (RFA), are increasingly used in the curative treatment of patients with colorectal liver metastases (CRLM). Selection bias plays an important role in the evaluation of early and late results between RFA and surgery. The purpose of this study was to evaluate recurrences and oncological survival following these two treatment modalities using single pair propensity score matching. METHODS: Between 2000 and 2018, patients curatively treated for CRLM were included in a multicentre database. Patients were excluded when receiving two-staged treatment, synchronous treatment with primary tumor or combination of modalities. Propensity score matching was used to minimize influence of known covariates, i.e., age, ASA, FONG CRS, location and T-stage of the primary tumor. RESULTS: Before matching, the RFA group contained 39 patients and the surgery group 982 patients, after matching both groups contained 36 patients. After matching, mean age was 69 years (53-86) for RFA and 68 (50-86) for surgery, with a mean tumor size of respectively 2.5 cm (0.8-6.5) and 3.4 cm (1-7.5). Both groups showed similar complication rate according to Clavien-Dindo (17vs.33%; p = 0.18), recurrence rate (58vs.64%; p = 0.09) without significant differences in 5-year DFS and OS (RFA compared to surgery respectively 25vs.37%; p = 0.09 and 42vs.53%; p = 0.09). CONCLUSION: After propensity score matching, RFA showed lower complications and similar oncological survival compared to surgical resection. In patients who are suboptimal candidates for surgery, RFA seems to be a good and safe alternative.
- Published
- 2022
20. Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO)
- Author
-
Görgec, B., Hansen, I., Kemmerich, G., Syversveen, T., Abu Hilal, M., Belt, E. J. T., Bisschops, R. H. C., Bollen, T. L., Bosscha, K., Burgmans, M. C., Cappendijk, V., de Boer, M. T., D’Hondt, M., Edwin, B., Gielkens, H., Grünhagen, D. J., Gillardin, P., Gobardhan, P. D., Hartgrink, H. H., Horsthuis, K., Kok, N. F. M., Kint, P. A. M., Kruimer, J. W. H., Leclercq, W. K. G., Lips, D. J., Lutin, B., Maas, M., Marsman, H. A., Morone, M., Pennings, J. P., Peringa, J., te Riele, W. W., Vermaas, M., Wicherts, D., Willemssen, F. E. J. A., Zonderhuis, B. M., Bossuyt, P. M. M., Swijnenburg, R. J., Fretland, A., Verhoef, C., Besselink, M. G., Stoker, J., Bnà, C., de Meyere, C., Draaisma, W. A., Gerhards, M. F., Imani, F., Kuhlmann, K. F. D., Liem, M. S. L., Meyer, Y., Surgery, Radiology & Nuclear Medicine, Graduate School, Radiology and Nuclear Medicine, AMS - Rehabilitation & Development, AMS - Sports, Amsterdam Gastroenterology Endocrinology Metabolism, Epidemiology and Data Science, APH - Methodology, APH - Personalized Medicine, CCA - Imaging and biomarkers, CCA - Cancer Treatment and Quality of Life, Radiology and nuclear medicine, Pathology, Obstetrics and gynaecology, CCA - Cancer Treatment and quality of life, AGEM - Re-generation and cancer of the digestive system, and VU University medical center
- Subjects
Gadolinium DTPA ,Cancer Research ,Colorectal cancer ,Gadoxetic acid ,Contrast Media ,Diagnostic accuracy ,Multimodal Imaging ,Liver MRI ,Study Protocol ,Liver metastases ,Prospective Studies ,FDG-PET ,RC254-282 ,OUTCOMES ,medicine.diagnostic_test ,Minimal clinically important difference ,Liver Neoplasms ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Magnetic Resonance Imaging ,Oncology ,SURVIVAL ,Radiology ,Colorectal Neoplasms ,Life Sciences & Biomedicine ,medicine.drug ,Adult ,medicine.medical_specialty ,STRATEGIES ,HEPATIC RESECTION ,SDG 3 - Good Health and Well-being ,Genetics ,medicine ,Humans ,In patient ,CANCER PATIENTS ,RADIOFREQUENCY ABLATION ,Liver surgery ,RECURRENCE ,Protocol (science) ,Science & Technology ,business.industry ,Abdominal CT scan ,Magnetic resonance imaging ,Diffusion weighted imaging ,PERFORMANCE ,medicine.disease ,Thermal ablation ,Colorectal liver metastases ,CONTRAST-ENHANCED CT ,Tomography, X-Ray Computed ,business ,Diffusion MRI - Abstract
Background Abdominal computed tomography (CT) is the standard imaging method for patients with suspected colorectal liver metastases (CRLM) in the diagnostic workup for surgery or thermal ablation. Diffusion-weighted and gadoxetic-acid-enhanced magnetic resonance imaging (MRI) of the liver is increasingly used to improve the detection rate and characterization of liver lesions. MRI is superior in detection and characterization of CRLM as compared to CT. However, it is unknown how MRI actually impacts patient management. The primary aim of the CAMINO study is to evaluate whether MRI has sufficient clinical added value to be routinely added to CT in the staging of CRLM. The secondary objective is to identify subgroups who benefit the most from additional MRI. Methods In this international multicentre prospective incremental diagnostic accuracy study, 298 patients with primary or recurrent CRLM scheduled for curative liver resection or thermal ablation based on CT staging will be enrolled from 17 centres across the Netherlands, Belgium, Norway, and Italy. All study participants will undergo CT and diffusion-weighted and gadoxetic-acid enhanced MRI prior to local therapy. The local multidisciplinary team will provide two local therapy plans: first, based on CT-staging and second, based on both CT and MRI. The primary outcome measure is the proportion of clinically significant CRLM (CS-CRLM) detected by MRI not visible on CT. CS-CRLM are defined as liver lesions leading to a change in local therapeutical management. If MRI detects new CRLM in segments which would have been resected in the original operative plan, these are not considered CS-CRLM. It is hypothesized that MRI will lead to the detection of CS-CRLM in ≥10% of patients which is considered the minimal clinically important difference. Furthermore, a prediction model will be developed using multivariable logistic regression modelling to evaluate the predictive value of patient, tumor and procedural variables on finding CS-CRLM on MRI. Discussion The CAMINO study will clarify the clinical added value of MRI to CT in patients with CRLM scheduled for local therapy. This study will provide the evidence required for the implementation of additional MRI in the routine work-up of patients with primary and recurrent CRLM for local therapy. Trial registration The CAMINO study was registered in the Netherlands National Trial Register under number NL8039 on September 20th 2019.
- Published
- 2021
21. Isolated limb perfusion by tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis: Perfusión aislada de la extremidad con factor de necrosis tumoral α y melfalán en pacientes con fibromatosis agresiva avanzada
- Author
-
van Broekhoven, D. L.M., Deroose, J. P., Bonvalot, S., Gronchi, A., Grünhagen, D. J., Eggermont, A. M.M., and Verhoef, C.
- Published
- 2014
22. Isolated limb perfusion using tumour necrosis factor α and melphalan in patients with advanced aggressive fibromatosis
- Author
-
van Broekhoven, D. L.M., Deroose, J. P., Bonvalot, S., Gronchi, A., Grünhagen, D. J., Eggermont, A. M.M., and Verhoef, C.
- Published
- 2014
- Full Text
- View/download PDF
23. Additional file 1 of Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study
- Author
-
Görgec, B., Hansen, I., Kemmerich, G., Syversveen, T., Abu Hilal, M., Belt, E. J. T., Bisschops, R. H. C., Bollen, T. L., Bosscha, K., Burgmans, M. C., Cappendijk, V., De Boer, M. T., D’Hondt, M., Edwin, B., Gielkens, H., Grünhagen, D. J., Gillardin, P., Gobardhan, P. D., Hartgrink, H. H., Horsthuis, K., Kok, N. F. M., Kint, P. A. M., Kruimer, J. W. H., Leclercq, W. K. G., Lips, D. J., Lutin, B., Maas, M., Marsman, H. A., Morone, M., Pennings, J. P., Peringa, J., Te Riele, W. W., Vermaas, M., Wicherts, D., Willemssen, F. E. J. A., Zonderhuis, B. M., Bossuyt, P. M. M., Swijnenburg, R. J., Fretland, Å. A., Verhoef, C., Besselink, M. G., and Stoker, J.
- Abstract
Additional file 1. SPIRIT checklist
- Published
- 2021
- Full Text
- View/download PDF
24. Additional file 2 of Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO): study protocol for an international multicentre prospective diagnostic accuracy study
- Author
-
Görgec, B., Hansen, I., Kemmerich, G., Syversveen, T., Abu Hilal, M., Belt, E. J. T., Bisschops, R. H. C., Bollen, T. L., Bosscha, K., Burgmans, M. C., Cappendijk, V., De Boer, M. T., D’Hondt, M., Edwin, B., Gielkens, H., Grünhagen, D. J., Gillardin, P., Gobardhan, P. D., Hartgrink, H. H., Horsthuis, K., Kok, N. F. M., Kint, P. A. M., Kruimer, J. W. H., Leclercq, W. K. G., Lips, D. J., Lutin, B., Maas, M., Marsman, H. A., Morone, M., Pennings, J. P., Peringa, J., Te Riele, W. W., Vermaas, M., Wicherts, D., Willemssen, F. E. J. A., Zonderhuis, B. M., Bossuyt, P. M. M., Swijnenburg, R. J., Fretland, Å. A., Verhoef, C., Besselink, M. G., and Stoker, J.
- Abstract
Additional file 2. Imaging Protocols of The Radiological Society of the Netherlands
- Published
- 2021
- Full Text
- View/download PDF
25. Predicting need for hospital-specific interventional care after surgery using electronic health record data
- Author
-
van de Sande, Davy, van Genderen, Michel E, Verhoef, C, van Bommel, Jasper, Gommers, Diederik, van Unen, Edwin, Huiskens, Joost, Grünhagen, D J, van de Sande, Davy, van Genderen, Michel E, Verhoef, C, van Bommel, Jasper, Gommers, Diederik, van Unen, Edwin, Huiskens, Joost, and Grünhagen, D J
- Abstract
BACKGROUND: A significant proportion of surgical inpatients is often admitted longer than necessary. Early identification of patients who do not need care that is strictly provided within hospitals would allow timely discharge of patients to a postoperative nursing home for further recovery. We aimed to develop a model to predict whether a patient needs hospital-specific interventional care beyond the second postoperative day.METHODS: This study included all adult patients discharged from surgical care in the surgical oncology department from June 2017 to February 2020. The primary outcome was to predict whether a patient still needs hospital-specific interventional care beyond the second postoperative day. Hospital-specific care was defined as unplanned reoperations, radiological interventions, and intravenous antibiotics administration. Different analytical methods were compared with respect to the area under the receiver-operating characteristics curve, sensitivity, specificity, positive predictive value, and negative predictive value.RESULTS: Each model was trained on 1,174 episodes. In total, 847 (50.5%) patients required an intervention during postoperative admission. A random forest model performed best with an area under the receiver-operating characteristics curve of 0.88 (95% confidence interval 0.83-0.93), sensitivity of 79.1% (95% confidence interval 0.67-0.92), specificity of 80.0% (0.73-0.87), positive predictive value of 57.6% (0.45-0.70) and negative predictive value of 91.7% (0.87-0.97).CONCLUSION: This proof-of-concept study found that a random forest model could successfully predict whether a patient could be safely discharged to a nursing home and does not need hospital care anymore. Such a model could aid hospitals in addressing capacity challenges and improve patient flow, allowing for timely surgical care.
- Published
- 2021
26. The age-related impact of surviving sarcoma on health-related quality of life:data from the SURVSARC study
- Author
-
Drabbe, C, Van der Graaf, W T A, De Rooij, B H, Grünhagen, D J, Soomers, V L M N, Van de Sande, M A J, Been, L B, Keymeulen, K B M I, van der Geest, I C M, Van Houdt, W J, Husson, O, Drabbe, C, Van der Graaf, W T A, De Rooij, B H, Grünhagen, D J, Soomers, V L M N, Van de Sande, M A J, Been, L B, Keymeulen, K B M I, van der Geest, I C M, Van Houdt, W J, and Husson, O
- Abstract
BACKGROUND: Health-related quality of life (HRQoL) data of sarcoma survivors are scarce and the impact of age remains unclear. The aims of this population-based study were to (i) compare HRQoL scores amongst three age-groups [adolescents and young adults (AYA, aged 18-39 years), older adults (OA, aged 40-69 years) and elderly (aged ≥70 years)]; (ii) compare HRQoL of each sarcoma survivor age group with an age- and sex-matched normative population sample; (iii) determine factors associated with low HRQoL per age group.METHODS: Dutch sarcoma survivors, who were 2-10 years after diagnosis, were invited to complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30-questions questionnaire on HRQoL.RESULTS: In total, 1099 survivors (58% response rate) completed the questionnaire: 186 AYAs, 748 OAs and 165 elderly. The median time since diagnosis for all patients was 5.2 years. Bone sarcomas were seen in 41% of AYAs, 22% of OAs and in 16% of elderly survivors (P < 0.01). AYA and OA survivors reported statistically significant and clinically meaningful worse physical, role, cognitive, emotional and social functioning compared with a matched norm population, which was not the case for elderly survivors. AYAs reported significantly worse scores on emotional and cognitive functioning compared with OA and elderly survivors. Malignant peripheral nerve sheath tumour, osteosarcoma and chordoma were the subtypes of which survivors reported the lowest HRQoL scores in comparison with the norm. For all age groups, chemotherapy, having a bone sarcoma and having comorbidities were most frequently associated with low scores on HRQoL subscales, whereas a shorter time since diagnosis was not.CONCLUSION: In this nationwide sarcoma survivorship study, the disease and its treatment had relatively more impact on the HRQoL of AYA and OA survivors than on elderly survivors. These results emphasise the need for personal
- Published
- 2021
27. Cost-effectiveness of adjuvant systemic therapies for patients with high-risk melanoma in Europe:a model-based economic evaluation
- Author
-
Mulder, E. E.A.P., Smit, L., Grünhagen, D. J., Verhoef, C., Sleijfer, S., van der Veldt, A. A.M., Uyl-de Groot, C. A., Mulder, E. E.A.P., Smit, L., Grünhagen, D. J., Verhoef, C., Sleijfer, S., van der Veldt, A. A.M., and Uyl-de Groot, C. A.
- Abstract
BACKGROUND: The introduction of adjuvant systemic treatment has significantly improved recurrence-free survival in patients with resectable high-risk melanoma. Adjuvant treatment with immune checkpoint inhibitors and targeted therapy, however, substantially impacts health care budgets, while the number of patients with melanoma who are treated in the adjuvant setting is still increasing. To evaluate the socioeconomic impact of the three adjuvant treatments, a cost-effectiveness analysis (CEA) was carried out.MATERIALS AND METHODS: Data were obtained from the three pivotal registration phase III clinical trials on the adjuvant treatment of patients with resected high-risk stage III in melanoma (KEYNOTE-054, CheckMate 238, and COMBI-AD). For this CEA, a Markov model with three health states (no evidence of disease, recurrent/progressive disease, and death) was applied. From a societal perspective, different adjuvant strategies were compared according to total costs, life years (LYs), quality-adjusted life years (QALYs), and incremental cost-effectiveness ratios. To evaluate model uncertainty, sensitivity analyses (deterministic and probabilistic) were carried out.RESULTS: In the adjuvant setting, total costs (per patient) were €168 826 for nivolumab, €194 529 for pembrolizumab, and €211 110 for dabrafenib-trametinib. These costs were mainly determined by drug acquisition costs, whereas routine surveillance costs varied from €126 096 to €134 945. Compared with routine surveillance, LYs improved by approximately 1.41 for all therapies and QALYs improved by 2.02 for immune checkpoint inhibitors and 2.03 for targeted therapy. This resulted in incremental cost-effectiveness ratios of €21 153 (nivolumab), €33 878 (pembrolizumab), and €37 520 (dabrafenib-trametinib) per QALY gained.CONCLUSIONS: This CEA compared the three EMA-approved adjuvant systemic therapies for resected stage III melanoma. Adjuvant treatment with nivolumab was the most cost-effec
- Published
- 2021
28. Clinical added value of MRI to CT in patients scheduled for local therapy of colorectal liver metastases (CAMINO):study protocol for an international multicentre prospective diagnostic accuracy study
- Author
-
Görgec, B, Hansen, I, Kemmerich, G, Syversveen, T, Abu Hilal, M, Belt, E J T, Bisschops, R H C, Bollen, T L, Bosscha, K, Burgmans, M C, Cappendijk, V, De Boer, M T, D'Hondt, M, Edwin, B, Gielkens, H, Grünhagen, D J, Gillardin, P, Gobardhan, P D, Hartgrink, H H, Horsthuis, K, Kok, N F M, Kint, P A M, Kruimer, J W H, Leclercq, W K G, Lips, D J, Lutin, B, Maas, M, Marsman, H A, Morone, M, Pennings, J P, Peringa, J, Te Riele, W W, Vermaas, M, Wicherts, D, Willemssen, F E J A, Zonderhuis, B M, Bossuyt, P M M, Swijnenburg, R J, Fretland, Å A, Verhoef, C, Besselink, M G, Stoker, J, Görgec, B, Hansen, I, Kemmerich, G, Syversveen, T, Abu Hilal, M, Belt, E J T, Bisschops, R H C, Bollen, T L, Bosscha, K, Burgmans, M C, Cappendijk, V, De Boer, M T, D'Hondt, M, Edwin, B, Gielkens, H, Grünhagen, D J, Gillardin, P, Gobardhan, P D, Hartgrink, H H, Horsthuis, K, Kok, N F M, Kint, P A M, Kruimer, J W H, Leclercq, W K G, Lips, D J, Lutin, B, Maas, M, Marsman, H A, Morone, M, Pennings, J P, Peringa, J, Te Riele, W W, Vermaas, M, Wicherts, D, Willemssen, F E J A, Zonderhuis, B M, Bossuyt, P M M, Swijnenburg, R J, Fretland, Å A, Verhoef, C, Besselink, M G, and Stoker, J
- Abstract
BACKGROUND: Abdominal computed tomography (CT) is the standard imaging method for patients with suspected colorectal liver metastases (CRLM) in the diagnostic workup for surgery or thermal ablation. Diffusion-weighted and gadoxetic-acid-enhanced magnetic resonance imaging (MRI) of the liver is increasingly used to improve the detection rate and characterization of liver lesions. MRI is superior in detection and characterization of CRLM as compared to CT. However, it is unknown how MRI actually impacts patient management. The primary aim of the CAMINO study is to evaluate whether MRI has sufficient clinical added value to be routinely added to CT in the staging of CRLM. The secondary objective is to identify subgroups who benefit the most from additional MRI.METHODS: In this international multicentre prospective incremental diagnostic accuracy study, 298 patients with primary or recurrent CRLM scheduled for curative liver resection or thermal ablation based on CT staging will be enrolled from 17 centres across the Netherlands, Belgium, Norway, and Italy. All study participants will undergo CT and diffusion-weighted and gadoxetic-acid enhanced MRI prior to local therapy. The local multidisciplinary team will provide two local therapy plans: first, based on CT-staging and second, based on both CT and MRI. The primary outcome measure is the proportion of clinically significant CRLM (CS-CRLM) detected by MRI not visible on CT. CS-CRLM are defined as liver lesions leading to a change in local therapeutical management. If MRI detects new CRLM in segments which would have been resected in the original operative plan, these are not considered CS-CRLM. It is hypothesized that MRI will lead to the detection of CS-CRLM in ≥10% of patients which is considered the minimal clinically important difference. Furthermore, a prediction model will be developed using multivariable logistic regression modelling to evaluate the predictive value of patient, tumor and procedural va
- Published
- 2021
29. Volume-outcome relationship of liver surgery:a nationwide analysis
- Author
-
Olthof, P B, Elfrink, A K E, Marra, E, Belt, E J T, van den Boezem, P B, Bosscha, K, Consten, E C J, den Dulk, M, Gobardhan, P D, Hagendoorn, J, van Heek, T N T, IJzermans, J N M, Klaase, J M, Kuhlmann, K F D, Leclercq, W K G, Liem, M S L, Manusama, E R, Marsman, H A, Mieog, J S D, Oosterling, S J, Patijn, G A, Te Riele, W, Swijnenburg, R-J, Torrenga, H, van Duijvendijk, P, Vermaas, M, Kok, N F M, Grünhagen, D J, Olthof, P B, Elfrink, A K E, Marra, E, Belt, E J T, van den Boezem, P B, Bosscha, K, Consten, E C J, den Dulk, M, Gobardhan, P D, Hagendoorn, J, van Heek, T N T, IJzermans, J N M, Klaase, J M, Kuhlmann, K F D, Leclercq, W K G, Liem, M S L, Manusama, E R, Marsman, H A, Mieog, J S D, Oosterling, S J, Patijn, G A, Te Riele, W, Swijnenburg, R-J, Torrenga, H, van Duijvendijk, P, Vermaas, M, Kok, N F M, and Grünhagen, D J
- Abstract
BACKGROUND: Evidence for an association between hospital volume and outcomes for liver surgery is abundant. The current Dutch guideline requires a minimum volume of 20 annual procedures per centre. The aim of this study was to investigate the association between hospital volume and postoperative outcomes using data from the nationwide Dutch Hepato Biliary Audit.METHODS: This was a nationwide study in the Netherlands. All liver resections reported in the Dutch Hepato Biliary Audit between 2014 and 2017 were included. Annual centre volume was calculated and classified in categories of 20 procedures per year. Main outcomes were major morbidity (Clavien-Dindo grade IIIA or higher) and 30-day or in-hospital mortality.RESULTS: A total of 5590 liver resections were done across 34 centres with a median annual centre volume of 35 (i.q.r. 20-69) procedures. Overall major morbidity and mortality rates were 11·2 and 2·0 per cent respectively. The mortality rate was 1·9 per cent after resection for colorectal liver metastases (CRLMs), 1·2 per cent for non-CRLMs, 0·4 per cent for benign tumours, 4·9 per cent for hepatocellular carcinoma and 10·3 per cent for biliary tumours. Higher-volume centres performed more major liver resections, and more resections for hepatocellular carcinoma and biliary cancer. There was no association between hospital volume and either major morbidity or mortality in multivariable analysis, after adjustment for known risk factors for adverse events.CONCLUSION: Hospital volume and postoperative outcomes were not associated.
- Published
- 2020
30. Preoperative imaging for colorectal liver metastases:a nationwide population-based study
- Author
-
Elfrink, A K E, Pool, M, van der Werf, L R, Marra, E, Burgmans, M C, Meijerink, M R, den Dulk, M, van den Boezem, P B, Te Riele, W W, Patijn, G A, Wouters, M W J M, Leclercq, W K G, Liem, M S L, Gobardhan, P D, Buis, C I, Kuhlmann, K F D, Verhoef, C, Besselink, M G, Grünhagen, D J, Klaase, J M, Kok, N F M, Elfrink, A K E, Pool, M, van der Werf, L R, Marra, E, Burgmans, M C, Meijerink, M R, den Dulk, M, van den Boezem, P B, Te Riele, W W, Patijn, G A, Wouters, M W J M, Leclercq, W K G, Liem, M S L, Gobardhan, P D, Buis, C I, Kuhlmann, K F D, Verhoef, C, Besselink, M G, Grünhagen, D J, Klaase, J M, and Kok, N F M
- Abstract
BACKGROUND: In patients with colorectal liver metastases (CRLM) preoperative imaging may include contrast-enhanced (ce) MRI and [18 F]fluorodeoxyglucose (18 F-FDG) PET-CT. This study assessed trends and variation between hospitals and oncological networks in the use of preoperative imaging in the Netherlands.METHODS: Data for all patients who underwent liver resection for CRLM in the Netherlands between 2014 and 2018 were retrieved from a nationwide auditing database. Multivariable logistic regression analysis was used to assess use of ceMRI, 18 F-FDG PET-CT and combined ceMRI and 18 F-FDG PET-CT, and trends in preoperative imaging and hospital and oncological network variation.RESULTS: A total of 4510 patients were included, of whom 1562 had ceMRI, 872 had 18 F-FDG PET-CT, and 1293 had combined ceMRI and 18 F-FDG PET-CT. Use of ceMRI increased over time (from 9·6 to 26·2 per cent; P < 0·001), use of 18 F-FDG PET-CT decreased (from 28·6 to 6·0 per cent; P < 0·001), and use of both ceMRI and 18 F-FDG PET-CT 16·9 per cent) remained stable. Unadjusted variation in the use of ceMRI, 18 F-FDG PET-CT, and combined ceMRI and 18 F-FDG PET-CT ranged from 5·6 to 100 per cent between hospitals. After case-mix correction, hospital and oncological network variation was found for all imaging modalities.DISCUSSION: Significant variation exists concerning the use of preoperative imaging for CRLM between hospitals and oncological networks in the Netherlands. The use of MRI is increasing, whereas that of 18 F-FDG PET-CT is decreasing.
- Published
- 2020
31. Isolated Limb Perfusions With Tumor Necrosis Factor and Melphalan for Locally Recurrent Soft Tissue Sarcoma in Previously Irradiated Limbs
- Author
-
Lans, T. E., Grünhagen, D. J., de Wilt, J. H. W., van Geel, A. N., and Eggermont, A. M. M.
- Published
- 2005
- Full Text
- View/download PDF
32. Long-term outcome of isolated limb perfusion with tumour necrosis factor-α for patients with melanoma in-transit metastases
- Author
-
Deroose, J. P., Grünhagen, D. J., van Geel, A. N., de Wilt, J. H. W., Eggermont, A. M. M., and Verhoef, C.
- Published
- 2011
- Full Text
- View/download PDF
33. Laparoscopic-monitored colonoscopic polypectomy: a multimodality method to avoid segmental colon resection
- Author
-
Grünhagen, D. J., van Ierland, M.-C. P., Doornebosch, P. G., Bruijninckx, M. M. M., Winograd, R., and de Graaf, E. J. R.
- Published
- 2011
- Full Text
- View/download PDF
34. Preoperative imaging for colorectal liver metastases: a nationwide population-based study
- Author
-
Elfrink, A K E, primary, Pool, M, additional, Werf, L R, additional, Marra, E, additional, Burgmans, M C, additional, Meijerink, M R, additional, Dulk, M, additional, Boezem, P B, additional, Riele, W W, additional, Patijn, G A, additional, Wouters, M W J M, additional, Leclercq, W K G, additional, Liem, M S L, additional, Gobardhan, P D, additional, Buis, C I, additional, Kuhlmann, K F D, additional, Verhoef, C, additional, Besselink, M G, additional, Grünhagen, D J, additional, Klaase, J M, additional, and Kok, N F M, additional
- Published
- 2020
- Full Text
- View/download PDF
35. Volume–outcome relationship of liver surgery: a nationwide analysis
- Author
-
Olthof, P B, primary, Elfrink, A K E, additional, Marra, E, additional, Belt, E J T, additional, van den Boezem, P B, additional, Bosscha, K, additional, Consten, E C J, additional, den Dulk, M, additional, Gobardhan, P D, additional, Hagendoorn, J, additional, van Heek, T N T, additional, IJzermans, J N M, additional, Klaase, J M, additional, Kuhlmann, K F D, additional, Leclercq, W K G, additional, Liem, M S L, additional, Manusama, E R, additional, Marsman, H A, additional, Mieog, J S D, additional, Oosterling, S J, additional, Patijn, G A, additional, te Riele, W, additional, Swijnenburg, R-J, additional, Torrenga, H, additional, van Duijvendijk, P, additional, Vermaas, M, additional, Kok, N F M, additional, Grünhagen, D J, additional, Besselink, M G H, additional, de Boer, M T, additional, Buis, C I, additional, van Gulik, T M, additional, Hoogwater, F J H, additional, Molenaar, I Q, additional, Dejong, C H C, additional, and Verhoef, C, additional
- Published
- 2020
- Full Text
- View/download PDF
36. Comment on: External validation of a prognostic model to predict survival of patients with sentinel node-negative melanoma
- Author
-
Verver, D, primary, Rekkas, A, additional, Grünhagen, D J, additional, and Verhoef, C, additional
- Published
- 2020
- Full Text
- View/download PDF
37. Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI
- Author
-
Vos, M, primary, Starmans, M P A, additional, Timbergen, M J M, additional, van der Voort, S R, additional, Padmos, G A, additional, Kessels, W, additional, Niessen, W J, additional, van Leenders, G J L H, additional, Grünhagen, D J, additional, Sleijfer, S, additional, Verhoef, C, additional, Klein, S, additional, and Visser, J J, additional
- Published
- 2019
- Full Text
- View/download PDF
38. Radiomics approach to distinguish between well differentiated liposarcomas and lipomas on MRI
- Author
-
Vos, M, Starmans, M P A, Timbergen, M J M, van der Voort, S R, Padmos, G A, Kessels, W, Niessen, W J, van Leenders, G J L H, Grünhagen, D J, Sleijfer, S, Verhoef, C, Klein, S, Visser, J J, Vos, M, Starmans, M P A, Timbergen, M J M, van der Voort, S R, Padmos, G A, Kessels, W, Niessen, W J, van Leenders, G J L H, Grünhagen, D J, Sleijfer, S, Verhoef, C, Klein, S, and Visser, J J
- Abstract
BACKGROUND: Well differentiated liposarcoma (WDLPS) can be difficult to distinguish from lipoma. Currently, this distinction is made by testing for MDM2 amplification, which requires a biopsy. The aim of this study was to develop a noninvasive method to predict MDM2 amplification status using radiomics features derived from MRI.METHODS: Patients with an MDM2-negative lipoma or MDM2-positive WDLPS and a pretreatment T1-weighted MRI scan who were referred to Erasmus MC between 2009 and 2018 were included. When available, other MRI sequences were included in the radiomics analysis. Features describing intensity, shape and texture were extracted from the tumour region. Classification was performed using various machine learning approaches. Evaluation was performed through a 100 times random-split cross-validation. The performance of the models was compared with the performance of three expert radiologists.RESULTS: The data set included 116 tumours (58 patients with lipoma, 58 with WDLPS) and originated from 41 different MRI scanners, resulting in wide heterogeneity in imaging hardware and acquisition protocols. The radiomics model based on T1 imaging features alone resulted in a mean area under the curve (AUC) of 0·83, sensitivity of 0·68 and specificity of 0·84. Adding the T2-weighted imaging features in an explorative analysis improved the model to a mean AUC of 0·89, sensitivity of 0·74 and specificity of 0·88. The three radiologists scored an AUC of 0·74 and 0·72 and 0·61 respectively; a sensitivity of 0·74, 0·91 and 0·64; and a specificity of 0·55, 0·36 and 0·59.CONCLUSION: Radiomics is a promising, non-invasive method for differentiating between WDLPS and lipoma, outperforming the scores of the radiologists. Further optimization and validation is needed before introduction into clinical practice.
- Published
- 2019
39. Histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy
- Author
-
Höppener, D J, Nierop, P M H, Herpel, E, Rahbari, N N, Doukas, M, Vermeulen, P B, Grünhagen, D J, Verhoef, C, Höppener, D J, Nierop, P M H, Herpel, E, Rahbari, N N, Doukas, M, Vermeulen, P B, Grünhagen, D J, and Verhoef, C
- Abstract
Colorectal liver metastases (CRLM) exhibit distinct histopathological growth patterns (HGPs) that are indicative of prognosis following surgical treatment. This study aims to assess the reliability and replicability of this histological biomarker. Within and between metastasis HGP concordance was analysed in patients who underwent surgery for CRLM. An independent cohort was used for external validation. Within metastasis concordance was assessed in CRLM with ≥ 2 tissue blocks. Similarly, concordance amongst multiple metastases was determined in patients with ≥ 2 resected CRLM. Diagnostic accuracy [expressed in area under the curve (AUC)] was compared by number of blocks and number of metastases scored. Interobserver agreement (Cohen's k) compared to the gold standard was determined for a pathologist and a PhD candidate without experience in HGP assessment after one and two training sessions. Both the within (95%, n = 825) and the between metastasis (90%, n = 363) HGP concordance was high. These results could be replicated in the external validation cohort with a within and between metastasis concordance of 97% and 94%, respectively. Diagnostic accuracy improved when scoring 2 versus 1 blocks(s) or CRLM (AUC = 95.9 vs. 97.7 [p = 0.039] and AUC = 96.5 vs. 93.3 [p = 0.026], respectively), but not when scoring 3 versus 2 blocks or CRLM (both p > 0.2). After two training sessions the interobserver agreement for both the pathologist and the PhD candidate were excellent (k = 0.953 and k = 0.951, respectively). The histopathological growth patterns of colorectal liver metastasis exhibit little heterogeneity and can be determined with a high diagnostic accuracy, making them a reliable and replicable histological biomarker.
- Published
- 2019
40. Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes
- Author
-
Verver, D, van Klaveren, D, Franke, V, van Akkooi, A C J, Rutkowski, P, Keilholz, U, Eggermont, A M M, Nijsten, T, Grünhagen, D J, Verhoef, C, Verver, D, van Klaveren, D, Franke, V, van Akkooi, A C J, Rutkowski, P, Keilholz, U, Eggermont, A M M, Nijsten, T, Grünhagen, D J, and Verhoef, C
- Abstract
BACKGROUND: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid in identifying patients who could benefit from a personalized treatment strategy. The objective was to construct and validate a nomogram for recurrence and melanoma-specific mortality (MSM) in patients with melanoma and negative SNs.METHODS: A total of 3220 patients with negative SNs were identified from a cohort of 4124 patients from four EORTC Melanoma Group centres who underwent sentinel lymph node biopsy. Prognostic factors for recurrence and MSM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c-index) and calibration in cross-validation across the four centres. A nomogram was developed for graphical presentation.RESULTS: There were 3180 eligible patients. The final prediction model for recurrence and the calibrated model for MSM included three independent prognostic factors: ulceration, anatomical location and Breslow thickness. The c-index was 0·74 for recurrence and 0·76 for the calibrated MSM model. Cross-validation across the four centres showed reasonable model performance. A nomogram was developed based on these models. One-third of the patients had a 5-year recurrence probability of 8·2 per cent or less, and one-third had a recurrence probability of 23·0 per cent or more.CONCLUSION: A nomogram for predicting recurrence and MSM in patients with melanoma and negative SNs was constructed and validated. It could provide personalized estimates useful for tailoring surveillance strategies (reduce or increase intensity), and selection of patients for adjuvant therapy or clinical trials.
- Published
- 2019
41. Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin
- Author
-
Verver, D, Madu, M F, Oude Ophuis, C M C, Faut, M, de Wilt, J H W, Bonenkamp, J J, Grünhagen, D J, van Akkooi, A C J, Verhoef, C, van Leeuwen, B L, Verver, D, Madu, M F, Oude Ophuis, C M C, Faut, M, de Wilt, J H W, Bonenkamp, J J, Grünhagen, D J, van Akkooi, A C J, Verhoef, C, and van Leeuwen, B L
- Abstract
BACKGROUND: The optimal extent of groin completion lymph node dissection (CLND) (inguinal or ilioinguinal dissection) in patients with melanoma is controversial. The aim of this study was to evaluate whether the extent of groin CLND after a positive sentinel node biopsy (SNB) is associated with improved outcome.METHODS: Data from all sentinel node-positive patients who underwent groin CLND at four tertiary melanoma referral centres were retrieved retrospectively. Baseline patient and tumour characteristics were collected for descriptive statistics, survival analyses and Cox proportional hazards regression analyses.RESULTS: In total, 255 patients were included, of whom 137 (53·7 per cent) underwent inguinal dissection and 118 (46·3 per cent) ilioinguinal dissection. The overall CLND positivity rate was 18·8 per cent; the inguinal positivity rate was 15·5 per cent and the pelvic positivity rate was 9·3 per cent. The pattern of recurrence, and 5-year melanoma-specific survival, disease-free survival and distant-metastasis free survival rates were similar for both dissection types, even for patients with a positive CLND result. Cox regression analysis showed that type of CLND was not associated with disease-free or melanoma-specific survival.CONCLUSION: There was no significant difference in recurrence pattern and survival rates between patients undergoing inguinal or ilioinguinal dissection after a positive SNB, even after stratification for a positive CLND result. An inguinal dissection is a safe first approach as CLND in patients with a positive SNB.
- Published
- 2018
42. Local excision of rectal cancer afterchemoradiation: feasibility depends on the primary stage
- Author
-
Burger, J. W. A., de Graaf, E. J. R., Doornebosch, P. G., Grünhagen, D. J., Biermann, K., de Wilt, J. H., and Verhoef, C.
- Published
- 2010
- Full Text
- View/download PDF
43. Development and validation of a nomogram to predict recurrence and melanoma-specific mortality in patients with negative sentinel lymph nodes
- Author
-
Verver, D, primary, van Klaveren, D, additional, Franke, V, additional, van Akkooi, A C J, additional, Rutkowski, P, additional, Keilholz, U, additional, Eggermont, A M M, additional, Nijsten, T, additional, Grünhagen, D J, additional, and Verhoef, C, additional
- Published
- 2018
- Full Text
- View/download PDF
44. Optimal extent of completion lymphadenectomy for patients with melanoma and a positive sentinel node in the groin
- Author
-
Verver, D, primary, Madu, M F, additional, Oude Ophuis, C M C, additional, Faut, M, additional, de Wilt, J H W, additional, Bonenkamp, J J, additional, Grünhagen, D J, additional, van Akkooi, A C J, additional, Verhoef, C, additional, and van Leeuwen, B L, additional
- Published
- 2017
- Full Text
- View/download PDF
45. Timing of completion lymphadenectomy after positive sentinel node biopsy in patients with melanoma
- Author
-
Oude Ophuis, C M C, primary, van Akkooi, A C J, additional, Rutkowski, P, additional, Powell, W E M, additional, Robert, C, additional, Testori, A, additional, van Leeuwen, B L, additional, Siegel, P, additional, Eggermont, A M M, additional, Verhoef, C, additional, and Grünhagen, D J, additional
- Published
- 2017
- Full Text
- View/download PDF
46. Development and validation of a nomogram to predict recurrence and melanoma‐specific mortality in patients with negative sentinel lymph nodes.
- Author
-
Verver, D., van Klaveren, D., Franke, V., van Akkooi, A. C. J., Rutkowski, P., Keilholz, U., Eggermont, A. M. M., Nijsten, T., Grünhagen, D. J., and Verhoef, C.
- Subjects
SENTINEL lymph nodes ,SENTINEL lymph node biopsy ,NOMOGRAPHY (Mathematics) - Abstract
Background: Patients with melanoma and negative sentinel nodes (SNs) have varying outcomes, dependent on several prognostic factors. Considering all these factors in a prediction model might aid in identifying patients who could benefit from a personalized treatment strategy. The objective was to construct and validate a nomogram for recurrence and melanoma‐specific mortality (MSM) in patients with melanoma and negative SNs. Methods: A total of 3220 patients with negative SNs were identified from a cohort of 4124 patients from four EORTC Melanoma Group centres who underwent sentinel lymph node biopsy. Prognostic factors for recurrence and MSM were studied with Cox regression analysis. Significant factors were incorporated in the models. Performance was assessed by discrimination (c‐index) and calibration in cross‐validation across the four centres. A nomogram was developed for graphical presentation. Results: There were 3180 eligible patients. The final prediction model for recurrence and the calibrated model for MSM included three independent prognostic factors: ulceration, anatomical location and Breslow thickness. The c‐index was 0·74 for recurrence and 0·76 for the calibrated MSM model. Cross‐validation across the four centres showed reasonable model performance. A nomogram was developed based on these models. One‐third of the patients had a 5‐year recurrence probability of 8·2 per cent or less, and one‐third had a recurrence probability of 23·0 per cent or more. Conclusion: A nomogram for predicting recurrence and MSM in patients with melanoma and negative SNs was constructed and validated. It could provide personalized estimates useful for tailoring surveillance strategies (reduce or increase intensity), and selection of patients for adjuvant therapy or clinical trials. Could personalize care [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
47. mRNA expression profiles of colorectal liver metastases as a novel biomarker for early recurrence after partial hepatectomy
- Author
-
van der Stok, E P, Smid, M, Sieuwerts, A M, Vermeulen, P B, Sleijfer, S, Ayez, N, Grünhagen, D J, Martens, J W M, Verhoef, C, van der Stok, E P, Smid, M, Sieuwerts, A M, Vermeulen, P B, Sleijfer, S, Ayez, N, Grünhagen, D J, Martens, J W M, and Verhoef, C
- Abstract
BACKGROUND: Identification of specific risk groups for recurrence after surgery for isolated colorectal liver metastases (CRLM) remains challenging due to the heterogeneity of the disease. Classical clinicopathologic parameters have limited prognostic value. The aim of this study was to identify a gene expression signature measured in CRLM discriminating early from late recurrence after partial hepatectomy.METHODS: CRLM from two patient groups were collected: I) with recurrent disease ≤12 months after surgery (N = 33), and II) without recurrences and disease free for ≥36 months (N = 30). The patients were clinically homogeneous; all had a low clinical risk score (0-2) and did not receive (neo-) adjuvant chemotherapy. Total RNA was hybridised to Illumina arrays, and processed for analysis. A leave-one-out cross validation (LOOCV) analysis was performed to identify a prognostic gene expression signature.RESULTS: LOOCV yielded an 11-gene profile with prognostic value in relation to recurrent disease ≤12 months after partial hepatectomy. This signature had a sensitivity of 81.8%, with a specificity of 66.7% for predicting recurrences (≤12 months) versus no recurrences for at least 36 months after surgery (X2 P < 0.0001).CONCLUSION: The current study yielded an 11-gene signature at mRNA level in CRLM discriminating early from late or no relapse after partial hepatectomy.
- Published
- 2016
48. Risk Factors for Positive Deep Pelvic Nodal Involvement in Patients with Palpable Groin Melanoma Metastases:Can the Extent of Surgery be Safely Minimized? : A Retrospective, Multicenter Cohort Study
- Author
-
Oude Ophuis, C M C, van Akkooi, A C J, Hoekstra, H J, Bonenkamp, J J, van Wissen, J, Niebling, M G, de Wilt, J H W, van der Hiel, B, van de Wiel, B, Koljenović, S, Grünhagen, D J, Verhoef, C, Oude Ophuis, C M C, van Akkooi, A C J, Hoekstra, H J, Bonenkamp, J J, van Wissen, J, Niebling, M G, de Wilt, J H W, van der Hiel, B, van de Wiel, B, Koljenović, S, Grünhagen, D J, and Verhoef, C
- Abstract
BACKGROUND: Patients with palpable melanoma groin metastases have a poor prognosis. There is debate whether a combined superficial and deep groin dissection (CGD) is necessary or if superficial groin dissection (SGD) alone is sufficient.AIM: The aim of this study was to analyze risk factors for deep pelvic nodal involvement in a retrospective, multicenter cohort of palpable groin melanoma metastases. This could aid in the development of an algorithm for selective surgery in the future.METHODS: This study related to 209 therapeutic CGDs from four tertiary centers in The Netherlands (1992-2013), selected based on complete preoperative imaging and pathology reports. Analyzed risk factors included baseline and primary tumor characteristics, total and positive number of inguinal nodes, inguinal lymph node ratio (LNR) and positive deep pelvic nodes on imaging (computed tomography [CT] ± positron emission tomography [PET], or PET - low-dose CT).RESULTS: Median age was 57 years, 54 % of patients were female, and median follow-up was 21 months (interquartile range [IQR] 11-46 months). Median Breslow thickness was 2.10 mm (IQR 1.40-3.40 mm), and 26 % of all primary melanomas were ulcerated. Positive deep pelvic nodes occurred in 35 % of CGDs. Significantly fewer inguinal nodes were positive in case of negative deep pelvic nodes (median 1 [IQR 1-2] vs. 3 [IQR 1-4] for positive deep pelvic nodes; p < 0.001), and LNR was significantly lower for negative versus positive deep pelvic nodes [median 0.15 (IQR 0.10-0.25) vs. 0.33 (IQR 0.14-0.54); p < 0.001]. A combination of negative imaging, low LNR, low number of positive inguinal nodes, and no extracapsular extension (ECE) could accurately predict the absence of pelvic nodal involvement in 84 % of patients.CONCLUSIONS: Patients with negative imaging, few positive inguinal nodes, no ECE, and low LNR have a low risk of positive deep pelvic nodes and may safely undergo SGD alone.
- Published
- 2015
49. Influence of Margins on Overall Survival After Hepatic Resection for Colorectal Metastasis
- Author
-
Kok, N. F. M., primary, Grünhagen, D. J., additional, Ayez, N., additional, and Verhoef, C., additional
- Published
- 2015
- Full Text
- View/download PDF
50. Local excision of rectal cancer afterchemoradiation: feasibility depends on the primary stage:feasibility depends on the primary stage
- Author
-
Burger, J W A, de Graaf, E J R, Doornebosch, P G, Grünhagen, D J, Biermann, K, de Wilt, J H, Verhoef, C, Burger, J W A, de Graaf, E J R, Doornebosch, P G, Grünhagen, D J, Biermann, K, de Wilt, J H, and Verhoef, C
- Published
- 2010
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.